Hospital or health organisation · founded 1981
Moffitt Cancer Center
Tampa, United States · moffitt.org
- Citations, last 5 years
- 134.7k
- Works, last 5 years
- 13.7k
- h-index
- 815
- Scientists listed
- 0
- Grants since 2016
- 1 073
Grants received
2022–2024 · research · R21
Developing GRB2-PROTACs for Treatment of Lung Cancer
Haitao Mark Ji · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy
Kosj Yamoah · Moffitt Cancer Center · funded by National Institutes of Health
2022–2024 · research · R21
The ODC A allele as a driver and therapeutic target of aggressive prostate cancer in African American men
Jong Y. Park · Moffitt Cancer Center · funded by National Institutes of Health
2022 · research · R03
Development and Validation of a Patient-Reported Measure Assessing Chimeric Antigen Receptor (CAR) T-Cell Therapy-Related Side Effects
Anna Barata · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R21
The ODC A allele as a driver and therapeutic target of aggressive prostate cancer in African American men
Jong Y. Park · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · award
Pre- and Post-Diagnosis Metformin Use and Ovarian Cancer Survival
Holly Harris · Moffitt Cancer Center · funded by American Cancer Society
2022–2027 · cooperative agreement · U01
Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS)
Dana Elise Rollison · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
Paulo Cesar Rodriguez · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · cooperative agreement · U01
Analytical tools for studying the tumor microenvironment leveraging spatial transcriptomics
Brooke L Fridley · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS)
Susan T Vadaparampil · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Novel Therapy to Inhibit IPMN Progression
Surinder K. Batra · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions
Mehdi Damaghi · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R01
Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation
Christine Vinci · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R01
Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
Antonio Luigi Amelio · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy
Noemi Andor · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions
Mehdi Damaghi · Moffitt Cancer Center · funded by National Institutes of Health
2022–2023 · research · R21
Characterization of the oncogenic potential of circRNAs in melanoma
Florian Karreth · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy
Thomas R. Bortfeld · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R00
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
Chang Jiang · Moffitt Cancer Center · funded by National Institutes of Health
2022–2023 · research · R21
Characterization of the oncogenic potential of circRNAs in melanoma
Florian Karreth · Moffitt Cancer Center · funded by National Institutes of Health
2022–2025 · research · R21
Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
Inna Smalley · Moffitt Cancer Center · funded by National Institutes of Health
2022 · career development · Young Investigator Award
The Effect of Nintedanib, Nivolumab, and Ipilimumab on the Peripheral Blood Immune-Phenotype and Tumor Microenvironment of Metastatic Non-Small Cell Lung Cancer
Brian Schlick · Moffitt Cancer Center · funded by Conquer Cancer Foundation
2022 · career development · Career Development Award
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in AML
Seongseok Yun · Moffitt Cancer Center · funded by Conquer Cancer Foundation
2022–2027 · research · R37
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy
Noemi Andor · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions
Mehdi Damaghi · Moffitt Cancer Center · funded by National Institutes of Health
2022–2026 · research · R00
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
Chang Jiang · Moffitt Cancer Center · funded by National Institutes of Health
2022–2028 · research · R01
Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study)
Anna R. Giuliano · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS)
Susan T Vadaparampil · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
Heather S.L. Jim · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Role of ULK3 in Sensitive and Refractory Multiple Myeloma
Conor C Lynch · Moffitt Cancer Center · funded by National Institutes of Health
2022–2028 · research · R01
Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study)
Anna R. Giuliano · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
Jonathan D. Licht · Moffitt Cancer Center · funded by National Institutes of Health
2022–2028 · research · R01
Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study)
Anna R. Giuliano · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy
Thomas R. Bortfeld · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
Antonio Luigi Amelio · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
Paulo Cesar Rodriguez · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation
Christine Vinci · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R37
Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy
Kosj Yamoah · Moffitt Cancer Center · funded by National Institutes of Health
2022–2027 · research · R01
A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury
Marcelo G. Bonini · Moffitt Cancer Center · funded by National Institutes of Health
2021–2023 · research · R21
RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER
Alvaro N Monteiro · Moffitt Cancer Center · funded by National Institutes of Health